Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes

Exclusion Criteria

• •1. Inability to provide informed consent
• •2. Patients with body mass index (BMI) \> 30, or weight \>100 kg
• •3. Patients with weight \<50 kg
• •4. Patients with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris.
• •5. Patients with uncontrolled hypertension (≥160/105 mmHg).
• •6. Patients with active on-going infections.
• •7. Patients with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has travelled in areas with high risk of tuberculosis or mycosis within the last 3 months.
• •8. Patients with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.
• •9. Patients with any immune suppressive treatment
• •10. Patients with known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease-
• •11. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
• •12. Patients with known, or previous, malignancy.
• •13. Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin.
• •14. Patients with GFR \<80 ml/min/1.73 m2 body surface.
• •15. Patients with proliferative retinopathy.
• •16. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with MSC.
• •17. Known hypersensitivity against any excipients, i.e. dimethyl sulfoxide (DMSO).